[Disseminated intravascular coagulation associated with vascular abnormalities].

This paper discusses the diagnostic findings and treatment options for DIC associated with vascular abnormalities based on the "Clinical practice guidelines for management of disseminated intravascular coagulation (DIC) in Japan 2024" released in early 2025. The guidelines define vascular abnormalities as aortic aneurysm, aortic dissection, vasculitis syndromes, and vascular malformations. DIC with enhanced fibrinolysis is a type of DIC often observed in association with vascular abnormalities. Key diagnostic tests for DIC include coagulation activation markers such as thrombin-antithrombin complexes and fibrinolysis activation markers such as plasmin-α2 plasmin inhibitor complex. Treatment consists of addressing the underlying disease, anticoagulant therapy, and combination therapy with anticoagulants and antifibrinolytics, or potentially observation, depending on bleeding symptoms and test results. Use of Factor XIII concentrates may also be considered. Treatment selection should consider the patient's condition and the treatment duration, with ongoing adjustments based on continuous testing. A well-established testing system and collaboration with experts are crucial in the treatment of DIC associated with vascular abnormalities.